https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26079 Wed 19 Jan 2022 15:17:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25616 Wed 17 Nov 2021 16:28:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24413 Wed 10 Nov 2021 15:14:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25882 Wed 10 Nov 2021 15:12:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26815 Wed 04 Sep 2019 10:52:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24336 .05 indicated statistical significance. An expert panel Delphi consensus (≥80%) was required for the endorsement of recommendations. Data Synthesis: All included studies were of high quality and analyzed the effects of multidisciplinary foot care, customized foot orthotics, and shoe inserts for the management of JIA. Custom-made foot orthotics and prefabricated shoe inserts displayed the greatest improvement in pain intensity, activity limitation, foot pain, and disability reduction (grades A, C+). Conclusions: The use of customized foot orthotics and prefabricated shoe inserts seems to be a good choice for managing foot pain and function in JIA.]]> Wed 04 Sep 2019 10:24:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27846 90, 60-90, and <60 mL/min/1.73 m², respectively). Outcomes: The effect of admission eGFR on the primary outcome of death or major disability at 90 days (defined as modified Rankin Scale scores of 3-6) was analyzed using a multivariable logistic regression model. Potential effect modification of intensive BP lowering treatment by admission eGFR was assessed by interaction terms. Results: Of 2,623 included participants, 912 (35%) and 280 (11%) had mildly and moderately/severely decreased eGFRs, respectively. Patients with moderately/severely decreased eGFRs had the greatest risk for death or major disability at 90 days (adjusted OR, 1.82; 95% CI, 1.28-2.61). Effects of early intensive BP lowering were consistent across different eGFRs (P = 0.5 for homogeneity). Limitations: Generalizability issues arising from a clinical trial population. Conclusions: Decreased eGFR predicts poor outcome in acute ICH. Early intensive BP lowering provides similar treatment effects in patients with ICH with decreased eGFRs.]]> Thu 09 Dec 2021 11:03:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17538 Sat 24 Mar 2018 08:03:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5094 Sat 24 Mar 2018 07:48:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27609 3-fold more likely to report adequate relief than those given placebo (odds ratio = 3.1; 95% confidence interval: 1.1-9.0). Neither amitriptyline nor escitalopram appeared to affect GE or meal-induced satiety after the 10-week period in any group. Subjects with delayed GE were less likely to report adequate relief than subjects with normal GE (odds ratio = 0.4; 95% confidence interval: 0.2-0.8). Both antidepressants improved overall quality of life. Conclusions Amitriptyline, but not escitalopram, appears to benefit some patients with FD, particularly those with ulcer-like (painful) FD. Patients with delayed GE do not respond to these drugs.]]> Sat 24 Mar 2018 07:39:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28471 Sat 24 Mar 2018 07:39:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27399 Sat 24 Mar 2018 07:34:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25723 Sat 24 Mar 2018 07:33:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27135 Sat 24 Mar 2018 07:33:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27132 Brachyspira in colonic biopsies, is uncommon and considered of doubtful significance. We aimed to determine the prevalence of CS in the general population, identify subtle colon pathologies, and evaluate a link with symptoms of IBS. Colonoscopy was performed in 745 subjects (aged 19-70 years, mean age 51 years, 43% male) with biopsies (ileum and 4 colonic sites) from a random population sample, Stockholm, Sweden, who completed a validated questionnaire of gastrointestinal symptoms; IBS was identified by Rome III criteria. CS was identified by histology and immunohistochemistry. In a general population, 17 individuals (2.28%; 95% confidence interval, 1.2%-3.5%) were diagnosed as having CS by histology; 6 (35%) had IBS. CS was always present in the sigmoid colon, but only 14 rectal biopsies. Eosinophils were increased in colon biopsies in CS cases versus controls, in the transverse (P =.02), sigmoid colon (P =.001), and rectum (P =.0005) with subepithelial eosinophil clusters (P =.053). Lymphoid follicles (at any site) were present in 13 CS (P =.0003). There was a 3-fold increased risk of IBS in CS (odds ratio, 3.59; 95% confidence interval, 1.27-10.11; P =.015). Polyps and diverticular disease were similar in CS cases and controls. The prevalence of CS in a general population is 2% and associated with nonconstipating IBS. Colonic eosinophilia with lymphoid follicles may signify the presence of CS.]]> Sat 24 Mar 2018 07:33:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27758 Sat 24 Mar 2018 07:27:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28204 Sat 24 Mar 2018 07:23:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27564 Sat 24 Mar 2018 07:23:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24418 18F] fluoro-2-deoxy-d-glucose positron emission tomography-computed tomography (FDG PET-CT) carried out in the third week (iPET) and after completion (pPET) of definitive radiation therapy in patients with mucosal primary head and neck squamous cell carcinoma (MPHNSCC) and to investigate the optimal visual grading criteria for therapy response assessment. Materials and methods: Sixty-nine consecutive patients with newly diagnosed MPHNSCC treated with radical radiation therapy with or without systemic therapy underwent staging. PET-CT, iPET and pPET were included. All PET-CT images were reviewed by using a visual grading system to assess metabolic response for primary tumour: 0 = similar to adjacent background blood pool activity; 1 = more than background but < mediastinal blood pool; 2 ≥ mediastinal blood pool and < liver; 3 ≥ liver; and 4 ≥ brain. The results were correlated with locoregional recurrence-free survival (LRFS), disease-free survival (DFS) and overall survival, using Kaplan-Meier analysis. Results: The median follow-up was 28 months (range 6-62), the median age was 61 years (range 39-81) and AJCC 7th edition clinical stage II, III and IV were six, 18 and 45 patients, respectively. The optimal threshold for non-complete metabolic response (non-CMR) was defined as focal uptake ≥ liver (grade 3) for iPET and focal uptake ≥ mediastinum (grade 2) for pPET. The 2 year Kaplan-Meier LRFS, DFS and overall survival estimates for primary CMR and non-CMR in iPET were 89.8% versus 71.5% (P = 0.062), 80.1% versus 65.3% (P = 0.132), 79.1% versus 72.1% (P = 0.328) and in pPET 86.2% versus 44.6% (P = 0.0005), 77.6% versus 41.2% (P = 0.006), 81.2% versus 40.6% (P = 0.01), respectively. The negative predictive value (NPV) for LRFS for patients achieving both primary and nodal CMR in iPET was 100%. No locoregional failure was observed in patients with both primary and nodal iPET CMR (P = 0.038), whereas those with nodal iPET CMR had no regional failure (P = 0.033). However, the positive predictive values (PPV) for LRFS and DFS for iPET and pPET were found to be poor: 30% and 36% for iPET and 35% and 39% for pPET, respectively. Conclusion: Standardised criteria using visual assessment are feasible. The metabolic response using visual assessment with standardised interpretation criteria of iPET and pPET can be useful predictors of tumour control. Dose de-escalation can be considered on the basis of a high NPV for iPET. However, the PPV of iPET is poor, indicating that additional discriminative tools are needed.]]> Sat 24 Mar 2018 07:14:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23601 Sat 24 Mar 2018 07:12:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24867 Sat 24 Mar 2018 07:11:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23765 Sat 24 Mar 2018 07:11:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27226 D-dimer may assist in early diagnosis, but fibrinogen levels often add little in the clinical setting. Bedside investigations would be ideal, but point-of-care testing international normalized ratio and whole blood clotting tests have been shown to be unreliable in VICC. The major complication of VICC is hemorrhage, including intracranial hemorrhage which is often fatal. The role of antivenom in VICC is controversial and may only be beneficial for some types of snakes including Echis spp where the duration of abnormal clotting is reduced from more than a week to 24 to 48 hours. In contrast, antivenom does not appear to speed the recovery of VICC in Australian snake envenoming. Other treatments for VICC include factor replacement, observation and prevention of trauma, and heparin. An Australian study showed that fresh-frozen plasma speeds recovery of VICC, but early use may increase consumption. There is no evidence to support heparin.]]> Mon 23 Jul 2018 13:17:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24367 Fri 22 Apr 2022 10:19:59 AEST ]]>